Form 483

Strategic Veterinary Pharmaceuticals, Inc. Form 483, 2009-11-23

FDA issued a Form 483 to Strategic Veterinary Pharmaceuticals, Inc. on 2009-11-23 with 5 public-safe observations.

483· Form 483 issued5 observations

Strategic Veterinary Pharmaceuticals, Inc. · Elwood, United States · Issued November 23, 2009

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

23 Nov 2009
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Shirley J Berryman, Tara L Breckenridge

23 Nov 2009
21 CFR 211.42(c)(10)(vi)

Equipment to control conditions

Cited by Shirley J Berryman, Tara L Breckenridge

23 Nov 2009
21 CFR 211.46(c)

Exhaust systems inadequate to control air contamination

Cited by Shirley J Berryman, Tara L Breckenridge

23 Nov 2009
21 CFR 211.100(b)

SOPs not followed / documented

Cited by Shirley J Berryman, Tara L Breckenridge

23 Nov 2009
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Shirley J Berryman, Tara L Breckenridge

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(b)Cited across public-safe Form 483 observations1x
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(vi)Cited across public-safe Form 483 observations1x
21 CFR 211.46(c)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere